Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis

Journal of Thoracic Oncology

Volumn 10, Issue 2, 2015, Pages 373-380

  Moreira, Andre L ^a   Won, Helen H ^a   Mcmillan, Robert ^a   Huang, James ^a   Riely, Gregory J ^a   Ladanyi, Marc ^a   Berger, Michael F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Next generation sequencing; Thymic carcinoma; Thymoma

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYLD GENE; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; KDM6A GENE; MALE; MLL2 GENE; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SETD2 GENE; SMAD4 GENE; SOMATIC MUTATION; THYMUS CANCER; TP53 GENE; TUMOR SUPPRESSOR GENE; DISEASE COURSE; GENETICS; MIDDLE AGED; MUTATION; PROGNOSIS; THYMOMA; TUMOR RECURRENCE;

ADULT; DISEASE PROGRESSION; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; THYMOMA; THYMUS NEOPLASMS;

EID: 84922240497     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000397     Document Type: Article

References (54)

1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5(10 Suppl 4):S260-S265
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris C C. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004
3. Masaoka A. Staging system of thymoma. J Thorac Oncol 2010;5(10 Suppl 4):S304-S312
4. Kim DJ, Yang WI, Choi SS, Kim KD, Chung KY. Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: A clinicopathologic study of 108 patients and literature review. Chest 2005;127:755-761
5. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients. Cancer 2002;94:624-632
6. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. J Thorac Oncol 2010;5:2017-2023
7. Okereke IC, Kesler KA, Freeman RK, et al. Thymic carcinoma: Outcomes after surgical resection. Ann Thorac Surg 2012;93:1668-72; discussion 1672
8. Riely GJ, Huang J. Induction therapy for locally advanced thymoma. J Thorac Oncol 2010;5(10 Suppl 4):S323-S326
9. G irard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799
10. Inoue M, Marx A, Zettl A, Ströbel P, Müller-Hermelink HK, Starostik P. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002;161:1507-1513
11. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715
12. Zettl A, Ströbel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266
13. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224
14. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-636
15. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356
16. Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006;52:261-262
17. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320
18. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol: ASCO Meeting Abstracts 2005;23
19. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375-381
20. Ströbel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626
21. G iaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009;4:1270-1273
22. Rajan A, Giaccone G. Targeted therapy for advanced thymic tumors. J Thorac Oncol 2010;5(10 Suppl 4):S361-S364
23. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93
24. Won HH, Scott SN, Brannon AR, et al. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp 2013:e50710
25. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: Clarification and definition of terms. J Thorac Oncol 2011;6(7 Suppl 3):S1710-S1716
26. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-1760
27. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-498
28. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011;24:1248-1253
29. Wheler J, Hong D, Swisher SG, et al. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: Responses to mTOR inhibitors and molecular analyses. Oncotarget 2013;4:890-898
30. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008;62:321-325
31. Petrini I, Zucali PA, Lee HS, et al. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 2010;5:1447-1453
32. Thomas de Montpreville V, Ghigna MR, Lacroix L, et al. Thymic carcinomas: Clinicopathologic study of 37 cases from a single institution. Virchows Arch 2013;462:307-313
33. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: From clinical management to targeted therapies. J Clin Oncol 2011;29:4820-4827
34. Kelly RJ. Thymoma versus thymic carcinoma: Differences in biology impacting treatment. J Natl Compr Canc Netw 2013;11:577-583
35. Petrini I, Rajan A, Pham T, et al. Whole genome and transcriptome sequencing of a B3 thymoma. PLoS One 2013;8:e60572
36. Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013;122:3169-3177
37. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013;15:2-8
38. Tateyama H, Eimoto T, Tada T, et al. p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol 1995;104:375-381
39. Hirabayashi H, Fujii Y, Sakaguchi M, et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73:639-644
40. Weissferdt A, Wistuba II, Moran CA. Molecular aspects of thymic carcinoma. Lung Cancer 2012;78:127-132
41. Yamamoto M, Hosoda M, Nakano K, et al. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 2014;105:81-88
42. Wang X, Chen JX, Liu JP, You C, Liu YH, Mao Q. Gain of function of mutant TP53 in glioblastoma: Prognosis and response to temozolomide. Ann Surg Oncol 2014;21:1337-1344
43. Clinical Lung Cancer Genome Project, Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013;5:209ra153
44. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-1646
45. Singh P, Srinivasan R, Wig JD. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2012;41:541-546
46. Poblete Gutiérrez P, Eggermann T, Höller D, et al. Phenotype diversity in familial cylindromatosis: A frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J Invest Dermatol 2002;119:527-531
47. Kim MS, Chung NG, Yoo NJ, Lee SH. Somatic mutation of CYLD gene is rare in hematologic and solid malignancies. Leuk Res 2011;35:e136-e137
48. Petrini I, Meltzer PS, Kim IK, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 2014;46:844-849
49. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43:1219-1223
50. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012;44:570-574
51. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488:106-110
52. G ui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875-878
53. Dawson MA, Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell 2012;150:12-27
54. Kubota M, Lin YW, Hamahata K, et al. Cancer chemotherapy and somatic cell mutation. Mutat Res 2000;470:93-102